<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Ovarian & Uterine Malignancies - Gynaecological Oncology Laboratory, HKU</title>
    <link rel="stylesheet" href="styles.css">
    <link href="https://fonts.googleapis.com/css2?family=Rock+Salt&family=Gochi+Hand&family=Handlee:wght@400;700&family=Caveat+Brush&display=swap" rel="stylesheet">
</head>
<body>
    <header class="header">
        <nav class="nav">
            <div class="nav-brand">
                <img src="logo/HKU_bilingual_logo.png" alt="The University of Hong Kong" class="university-logo">
                <div class="lab-info">
                    <h1>Gynaecological Oncology Laboratory</h1>
                    <p class="dept-name">Department of Obstetrics & Gynaecology</p>
                </div>
            </div>
            <ul class="nav-menu">
                <li><a href="index.html">Home</a></li>
                <li><a href="index.html#about">About</a></li>
                <li><a href="index.html#research">Research</a></li>
                <li><a href="team.html">Team</a></li>
                <li><a href="index.html#publications">Publications</a></li>
                <li><a href="http://localhost:8501" target="_blank" class="data-exploration-btn">Data</a></li>
                <li><a href="index.html#contact">Contact</a></li>
            </ul>
        </nav>
    </header>

    <main>
        <section class="hero-subpage">
            <div class="container">
                <div class="breadcrumb">
                    <a href="index.html">Home</a> > <span>Ovarian & Uterine Malignancies</span>
                </div>
                <h1>Ovarian & Uterine Malignancies</h1>
                <p class="subpage-subtitle">Comprehensive research and clinical management of epithelial ovarian cancer, endometrial carcinomas, and gynecological malignancies</p>
            </div>
        </section>

        <section class="section">
            <div class="container">
                <div class="content-layout">
                    <div class="main-content">
                        <h2 class="gloria-title">Overview</h2>
                        <p>Our Ovarian & Uterine Malignancies program represents one of the leading centers in Asia for comprehensive care and research of gynecological cancers. We handle the largest volume of ovarian and endometrial cancer cases in Hong Kong, with 194 new cases in 2023 alone, providing world-class multidisciplinary care and conducting cutting-edge research.</p>

                        <h2 class="gloria-title">Clinical Volume (2023)</h2>
                        <div class="stats-grid">
                            <div class="stat-card">
                                <h3>61</h3>
                                <p>Epithelial Ovarian Cancer Cases</p>
                            </div>
                            <div class="stat-card">
                                <h3>133</h3>
                                <p>Endometrial Cancer Cases</p>
                            </div>
                            <div class="stat-card">
                                <h3>14</h3>
                                <p>Primary Peritoneal Cancer Cases</p>
                            </div>
                            <div class="stat-card">
                                <h3>10</h3>
                                <p>Ovarian Borderline Tumors</p>
                            </div>
                        </div>

                        <h2 class="gloria-title">Epithelial Ovarian Cancer</h2>
                        <div class="cancer-section">
                            <h3>Staging Distribution (2023)</h3>
                            <div class="staging-info">
                                <div class="stage-item">
                                    <strong>Stage I:</strong> 22 cases (36.1%) - Early stage, confined to ovaries
                                </div>
                                <div class="stage-item">
                                    <strong>Stage II:</strong> 5 cases (8.2%) - Limited pelvic extension
                                </div>
                                <div class="stage-item">
                                    <strong>Stage III:</strong> 11 cases (18.0%) - Abdominal spread
                                </div>
                                <div class="stage-item">
                                    <strong>Stage IV:</strong> 6 cases (9.8%) - Distant metastases
                                </div>
                            </div>

                            <h3>Age Distribution</h3>
                            <p>Peak incidence in the 51-60 age group (23 cases, 37.7%), with significant representation across all adult age groups from 31-80 years.</p>
                        </div>

                        <h2 class="gloria-title">Endometrial Cancer</h2>
                        <div class="cancer-section">
                            <h3>Staging Distribution (2023)</h3>
                            <div class="staging-info">
                                <div class="stage-item">
                                    <strong>Stage I:</strong> 67 cases (50.4%) - Confined to uterus
                                </div>
                                <div class="stage-item">
                                    <strong>Stage II:</strong> 20 cases (15.0%) - Cervical involvement
                                </div>
                                <div class="stage-item">
                                    <strong>Stage III:</strong> 21 cases (15.8%) - Regional spread
                                </div>
                                <div class="stage-item">
                                    <strong>Stage IV:</strong> 13 cases (9.8%) - Distant spread
                                </div>
                            </div>

                            <h3>Age Distribution</h3>
                            <p>Predominantly affects postmenopausal women, with peak incidence in the 51-60 age group (50 cases, 37.6%) and continued high rates in the 61-70 group (35 cases, 26.3%).</p>
                        </div>

                        <h2 class="gloria-title">Other Uterine Malignancies (2023)</h2>
                        <div class="other-malignancies">
                            <div class="malignancy-item">
                                <h4>Malignant Mixed MÃ¼llerian Tumor (MMMT)</h4>
                                <p>6 cases - Aggressive biphasic tumors requiring multimodal therapy</p>
                            </div>
                            <div class="malignancy-item">
                                <h4>Smooth Muscle Tumors</h4>
                                <p>5 STUMP cases, 3 leiomyosarcoma cases - Rare mesenchymal tumors</p>
                            </div>
                            <div class="malignancy-item">
                                <h4>Endometrial Stromal Sarcoma</h4>
                                <p>2 cases - Low-grade stromal malignancies</p>
                            </div>
                        </div>

                        <h2 class="gloria-title">Specialized Treatment Approaches</h2>
                        <div class="treatment-grid">
                            <div class="treatment-item">
                                <h4>Cytoreductive Surgery</h4>
                                <p>Advanced debulking procedures including HIPEC (Hyperthermic Intraperitoneal Chemotherapy) for selected cases</p>
                            </div>
                            <div class="treatment-item">
                                <h4>Minimally Invasive Surgery</h4>
                                <p>Da Vinci robotic surgery for complex staging procedures and radical hysterectomies</p>
                            </div>
                            <div class="treatment-item">
                                <h4>Targeted Therapies</h4>
                                <p>PARP inhibitors (62 patients in 2023), bevacizumab, and immunotherapy protocols</p>
                            </div>
                            <div class="treatment-item">
                                <h4>Clinical Trials</h4>
                                <p>Active participation in international trials including GOG and ENGOT studies</p>
                            </div>
                        </div>

                        <h2 class="gloria-title">Research Focus Areas</h2>
                        <div class="research-areas">
                            <div class="research-area">
                                <h3>Biomarker Discovery</h3>
                                <p>Advanced proteomics and genomics research to identify predictive biomarkers for treatment response and prognosis in ovarian and endometrial cancers.</p>
                            </div>
                            <div class="research-area">
                                <h3>Patient-Derived Organoids</h3>
                                <p>Cutting-edge 3D organoid culture systems to model patient tumors for personalized therapy testing and drug discovery.</p>
                            </div>
                            <div class="research-area">
                                <h3>Immunotherapy Research</h3>
                                <p>Investigation of immune checkpoint inhibitors and combination therapies, particularly in microsatellite instability-high tumors.</p>
                            </div>
                            <div class="research-area">
                                <h3>Patient-Initiated Follow-Up</h3>
                                <p>Innovative follow-up strategies empowering patients to initiate care when needed, improving quality of life and resource utilization.</p>
                            </div>
                        </div>
                    </div>

                    <div class="sidebar">
                        <div class="sidebar-card">
                            <h3>Key Statistics</h3>
                            <ul>
                                <li>194 new cases annually</li>
                                <li>Leading volume in Hong Kong</li>
                                <li>Multidisciplinary team approach</li>
                                <li>HIPEC capability</li>
                                <li>Clinical trial access</li>
                                <li>PARP inhibitor expertise</li>
                            </ul>
                        </div>

                        <div class="sidebar-card">
                            <h3>Related Publications (2023)</h3>
                            <div class="publication-item">
                                <h4>Intraperitoneal Carboplatin for Ovarian Cancer</h4>
                                <p>NEJM Evid. 2023;2(5):EVIDoa2200225</p>
                            </div>
                            <div class="publication-item">
                                <h4>Patient-derived Organoid Culture</h4>
                                <p>Cancer Med. 2023;12(19):19714-19731</p>
                            </div>
                            <div class="publication-item">
                                <h4>Patient-Initiated Follow-Up</h4>
                                <p>Curr Oncol. 2023;30(4):3627-3636</p>
                            </div>
                        </div>

                        <div class="sidebar-card">
                            <h3>Treatment Innovations</h3>
                            <ul>
                                <li>HIPEC procedures</li>
                                <li>Da Vinci robotic surgery</li>
                                <li>Sentinel lymph node biopsy</li>
                                <li>Advanced imaging protocols</li>
                                <li>Molecular tumor profiling</li>
                            </ul>
                        </div>

                        <div class="sidebar-card">
                            <h3>Contact</h3>
                            <p>For referrals or consultations:</p>
                            <p><strong>Location:</strong> Queen Mary Hospital<br>
                            <strong>Follow-up Clinic:</strong> Weekly sessions<br>
                            <strong>Multidisciplinary Team:</strong> Weekly meetings</p>
                        </div>
                    </div>
                </div>
            </div>
        </section>
    </main>

    <footer class="footer">
        <div class="container">
            <p>&copy; 2024 Gynaecological Oncology Laboratory, Department of Obstetrics & Gynaecology, The University of Hong Kong. All rights reserved.</p>
        </div>
    </footer>

    <script src="script.js"></script>
</body>
</html>